BIOAVLEE AND BIOCELTIX IN THE TOP 5 POLISH START-UP LIFESCIENCE

 

 

 

 

 

 

 

Biotechnologia.pl – a specialized industry portal – published a list of 5 Polish start-ups from the LifeScience industry, whose solutions can change the world. Among them were two start-ups present in Leonarto’s portfolio – Bioavlee and Bioceltix. ­čĹĆ As the editorial board writes – “(…) in Poland there were swarms of biotechnological and telemedicine start-ups, attracting investors and a wide stream of subsidies. The game is worth the candle – in the case of success, these projects will be worth billions. ”

We believe that this is how it will be. We invest in innovative industries as well as ambitious and ground-breaking projects whose implementations are carried out on a massive scale. Ambition and innovation are part of our DNA!

LEONARTO ALFA WITH INVESTMENT IN ED-TECH. THE NEW PORTFOLIO COMPANY – UNIVERSALITY











CAREER STARTS NOW AT STUDIES ­čÄô

Universality supports recruitment processes and competence development of students – future candidates for work during their studies. Universality.io platform is the largest database of practical programming tasks prepared by companies, available to lecturers enabling students at universities to acquire practical knowledge quickly┬áand effectively. As part of the investment the team of Universality, lead by the project’s initiator – Jurek Czepiel, will develop a completely new functionality – AI Driven HR, which will be implemented in the form of a smart student and recruiter assistant. Universality’s strategy for the coming years assumes dynamic growth both among the universities┬áas well as corporate clients.

Welcome Universality team on board and we will keep our fingers crossed for achieving goals Leonarto Alfa investment implemented in cooperation with #NCBR as part of the #BridgeAlfa program. National Center for Research and Development, thank you!

 

 

GENOMTEC – WINNER, BIOTTS – AWARDED, START-UP-MED COMPETITION RESOLVED

The Start-Up-Med competition is an event accompanying the Congress of Health Challenges. The aim of the competition is to select and distinguish start-ups – the most creative authors of innovative and at the same time to identify effective projects covering broadly understood medical technologies, both drug and non-drug (including medical devices, solutions in the field of diagnostics and teleinformation technologies), as well as organizational innovations that improve the functioning of various areas of the health care system.

As part of this year’s edition, the finalists included two companies from the Leonarto portfolio, GENOMTEC with the GENOMTEC ID and BIOTTS with their innovative transdermal system increasing the bioavailability of active substances. The jury of scientific experts, clinicians, Ministry of Health representatives, Agency for Health Technology Assessment and Tariffs, National Center for Research and Development, and leaders of the national medical industry, favoured GENOMTEC ID­čĆćÔÇö> the best solutions.

We congratulate both GENOMTEC and BIOTTS and wish you continued success in the development of innovative products and their commercialization.

Contact us